

		Sara Lisa Hennicken	Shervin J. Korangy	Dr. Marcus Kuhnert	Michael Sen	Gregory Sorensen, M.D.	Pascale Witz
	Exercised Profession ¹ :	Member of the Management Board (Chief Financial Officer) of Fresenius Management SE (general partner of Fresenius SE & Co. KGaA (listed))	President and Chief Executive Officer of BVI Medical, Inc., USA	Member of the Executive Board and Chief Financial Officer of MERCK Kommanditgesellschaft auf Aktien (listed) (until June 30, 2023) and of the Executive Board of E. Merck KG (until July 31, 2024)	Member and Chairman of the Management Board of Fresenius Management SE (general partner of Fresenius SE & Co. KGaA (listed))	Chief Executive Officer of DeepHealth, Inc., USA, and Executive Chairman of the Board of Directors of IMRIS (Deerfield Imaging, Inc.), USA	President of PWH Advisors LLC, USA
	Member since:	(2022) ² / n.a.	n.a.	n.a.	(2022) ² / n.a.	2021	2016
	Independence ³		✓	✓		✓	✓
	Time availability and limitation of the number of mandates ⁴	✓	✓	✓	✓	✓	✓
Diversity	Gender	F	M	M	M	M	F
	Year of birth (Standard age limit: 75 years)	1980	1974	1968	1968	1962	1967
	Nationality	German	U.S.-American	German and U.S.-American	German	U.S.-American	French
	Educational Background	Economics	Economics	Business Administration and Mechanical Engineering	Business Administration	Medicine	Biochemistry and Business Administration
Profile of Skills and Expertise: Individual knowledge / experience	Corporate management	✓	✓	✓	✓	✓	✓
	Sector knowledge and understanding of global activities	✓	✓	✓	✓	✓	✓
	Command of the English language	✓	✓	✓	✓	✓	✓
Profile of Skills and Expertise: Requirements for the entire Supervisory Board	Sector experience	✓	✓	✓	✓	✓	✓
	Financial knowledge: Accounting	✓	✓	✓	✓	✓	✓

		Sara Lisa Hennicken	Shervin J. Korangy	Dr. Marcus Kuhnert	Michael Sen	Gregory Sorensen, M.D.	Pascale Witz
	Financial knowledge: Auditing	✓	✓	✓	✓	✓	✓
	Legal, Regulatory, Compliance	✓	✓	✓	✓	✓	✓
	Sustainability	✓	✓	✓	✓	✓	✓
	Digitalization	✓	✓	✓	✓	✓	✓
	Internationality	✓	✓	✓	✓	✓	✓
	Management experience	✓	✓	✓	✓	✓	✓
Other Mandates^{1,7,8}	Mandates in statutory supervisory boards	<ul style="list-style-type: none"> Fresenius Medical Care Management AG⁵ Fresenius Kabi AG (Deputy Chair) 	<ul style="list-style-type: none"> none 	<ul style="list-style-type: none"> none 	<ul style="list-style-type: none"> Fresenius Medical Care Management AG⁵ (Chair) Fresenius Kabi AG (Chair) 	<ul style="list-style-type: none"> Fresenius Medical Care Management AG⁵ Fresenius Medical Care AG & Co. KGaA⁶ 	<ul style="list-style-type: none"> Fresenius Medical Care Management AG⁵ Fresenius Medical Care AG & Co. KGaA⁶
	Mandates in comparable domestic or foreign supervisory bodies of commercial enterprises	<ul style="list-style-type: none"> VAMED AG, Austria (Deputy Chair) 	<ul style="list-style-type: none"> BVI Group Ltd., USA Hain Celestial Group, Inc., USA (listed) Motus GI Holdings, Inc., USA (listed) 	<ul style="list-style-type: none"> Döhler Group SE 	<ul style="list-style-type: none"> none 	<ul style="list-style-type: none"> REALM IDx, Inc., USA 	<ul style="list-style-type: none"> Horizon Therapeutics plc, Ireland (listed) Regulus Therapeutics, Inc., USA (listed) Revvity, Inc., USA (listed)

¹ Unless otherwise indicated, all activities/mandates stated here relate to companies domiciled in Germany that are not listed on the stock exchange.

² Michael Sen and Sara Lisa Hennicken are each not a member of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA (Company) but have each been a member (and, with respect to Michael Sen, the Chair) of the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of the Company, since 2022. The Supervisory Board of Fresenius Medical Care Management AG has so far been partly responsible for tasks for which the Supervisory Board of the Company in its legal form of a stock corporation with the company name Fresenius Medical Care AG will be responsible in the future.

³ According to the German Corporate Governance Code in the version of April 28, 2022 (GCGC). Michael Sen and Sara Lisa Hennicken are each a member of the Management Board of Fresenius Management SE, the general partner of Fresenius SE & Co. KGaA. Fresenius SE & Co. KGaA holds approximately 32.2% of the share capital and the voting rights of the Company. Even after the effectiveness of the conversion, the Company will continue to have a material business relationship with Fresenius SE & Co. KGaA or its affiliated companies. Michael Sen und Sara Lisa Hennicken are therefore, as a matter of precaution, not considered independent within the meaning of recommendation C.7 of the GCGC.

⁴ According to the German Stock Corporation Act and the GCGC.

⁵ Fresenius Medical Care Management AG is the General Partner of the Company and will cease to be the General Partner upon the change of the legal form of the Company into a stock corporation with the company name Fresenius Medical Care AG becoming effective.

⁶ The mandate ends in each case when the change of the legal form of the Company into a stock corporation with the company name Fresenius Medical Care AG takes effect.

⁷ In each case „non-executive“.

⁸ Fresenius Medical Care Management AG, Fresenius Kabi AG and VAMED AG are each – like the Company – group companies of Fresenius SE. Upon the change of the legal form of the Company into a stock corporation becoming effective and the resulting deconsolidation, the Company will cease to be a member of the group of Fresenius SE and its aforementioned group companies.